Switching from Epoetin Alfa (Epogen ®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.

CONCLUSIONS: Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294). PMID: 30196301 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30196301?dopt=Abstract

Source: American Journal of Nephrology - September 7, 2018 Category: Urology & Nephrology Authors: Thadhani R, Guilatco R, Hymes J, Maddux FW, Ahuja A Tags: Am J Nephrol Source Type: research